MetaCap

Citius Pharmaceuticals (CTXR) vs Seres Therapeutics (MCRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTXR+1.48%MCRB-54.41%
+18%-20%-58%
Oct 7, 20261 yearNov 20, 2026
CTXR+1.82%MCRB-54.24%
+12%-23%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTXR versus MCRB key metrics
MetricCTXRMCRB
Share price$0.5085$1.24
Market cap$13.96M$12.64M
1-day change+2.27%-6.77%
YTD return-34.56%—
1-year return-55.39%—
5-year return-98.79%—
EPS (TTM)$-1.75$-5.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$789.00K
Net income (latest FY)$-39.74M$5.70M
Operating margin—-11910.14%
Net margin—721.93%
52-week high$1.54$18.86
52-week low$0.37$1.20
Distance from 52-week high-66.98%-93.43%
Analyst consensusnonenone
Avg. price target upside+686.63%+1270.97%
Average volume275.44K74.83K
Shares outstanding27.45M10.20M
Employees2366
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

CTXR vs MCRB FAQ

Which is bigger, Citius Pharmaceuticals or Seres Therapeutics?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $12.64M for Seres Therapeutics (MCRB).

Are Citius Pharmaceuticals and Seres Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons